


PHARMACEUTICAL 2022

AVEO PHARMACEUTICALS INC. Rank 307 of 475









PHARMACEUTICAL 2022

AVEO PHARMACEUTICALS INC. Rank 307 of 475



The relative strengths and weaknesses of AVEO PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVEO PHARMACEUTICALS INC. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 113% points. The greatest weakness of AVEO PHARMACEUTICALS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 144% points.

The company's Economic Capital Ratio, given in the ranking table, is -202%, being 75% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	104,736
Cost of Goods Sold	4,737
Intangible Assets	0
Liabilities, Current	18,731
Liabilities, Non-Current	2,780
Other Assets	329
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	37,960
Other Net Income	-3,788
Property and Equipment	276
Research and Development	26,298
Revenues	42,295
Selling, General and Administrative Expense	60,814

Output Variable	Value in 1000 USD
Assets	105,341
Liabilities	59,471
Expenses	91,849
Stockholders Equity	45,870
Net Income	-53,342
Comprehensive Net Income	-53,344
Economic Capital Ratio	-202%

